JP2020510011A5 - - Google Patents

Download PDF

Info

Publication number
JP2020510011A5
JP2020510011A5 JP2019548370A JP2019548370A JP2020510011A5 JP 2020510011 A5 JP2020510011 A5 JP 2020510011A5 JP 2019548370 A JP2019548370 A JP 2019548370A JP 2019548370 A JP2019548370 A JP 2019548370A JP 2020510011 A5 JP2020510011 A5 JP 2020510011A5
Authority
JP
Japan
Prior art keywords
glucocorticoid receptor
patient
composition
composition according
administered
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2019548370A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020510011A (ja
JP7564620B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2018/021592 external-priority patent/WO2018165460A1/en
Publication of JP2020510011A publication Critical patent/JP2020510011A/ja
Publication of JP2020510011A5 publication Critical patent/JP2020510011A5/ja
Priority to JP2022070027A priority Critical patent/JP2022090003A/ja
Priority to JP2024053332A priority patent/JP2024074854A/ja
Application granted granted Critical
Publication of JP7564620B2 publication Critical patent/JP7564620B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2019548370A 2017-03-09 2018-03-08 カテコールアミン分泌腫瘍の処置における糖質コルチイド受容体モジレータの使用 Active JP7564620B2 (ja)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2022070027A JP2022090003A (ja) 2017-03-09 2022-04-21 カテコールアミン分泌腫瘍の処置における糖質コルチイド受容体モジレータの使用
JP2024053332A JP2024074854A (ja) 2017-03-09 2024-03-28 カテコールアミン分泌腫瘍の処置における糖質コルチイド受容体モジレータの使用

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762469296P 2017-03-09 2017-03-09
US62/469,296 2017-03-09
PCT/US2018/021592 WO2018165460A1 (en) 2017-03-09 2018-03-08 Use of glucocorticoid receptor modulators in the treatment of catecholamine-secreting tumors

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2022070027A Division JP2022090003A (ja) 2017-03-09 2022-04-21 カテコールアミン分泌腫瘍の処置における糖質コルチイド受容体モジレータの使用

Publications (3)

Publication Number Publication Date
JP2020510011A JP2020510011A (ja) 2020-04-02
JP2020510011A5 true JP2020510011A5 (https=) 2021-02-18
JP7564620B2 JP7564620B2 (ja) 2024-10-09

Family

ID=63446773

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2019548370A Active JP7564620B2 (ja) 2017-03-09 2018-03-08 カテコールアミン分泌腫瘍の処置における糖質コルチイド受容体モジレータの使用
JP2022070027A Withdrawn JP2022090003A (ja) 2017-03-09 2022-04-21 カテコールアミン分泌腫瘍の処置における糖質コルチイド受容体モジレータの使用
JP2024053332A Pending JP2024074854A (ja) 2017-03-09 2024-03-28 カテコールアミン分泌腫瘍の処置における糖質コルチイド受容体モジレータの使用

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2022070027A Withdrawn JP2022090003A (ja) 2017-03-09 2022-04-21 カテコールアミン分泌腫瘍の処置における糖質コルチイド受容体モジレータの使用
JP2024053332A Pending JP2024074854A (ja) 2017-03-09 2024-03-28 カテコールアミン分泌腫瘍の処置における糖質コルチイド受容体モジレータの使用

Country Status (8)

Country Link
US (1) US11045482B2 (https=)
EP (1) EP3592358A4 (https=)
JP (3) JP7564620B2 (https=)
CN (1) CN110475558A (https=)
AU (1) AU2018230429B2 (https=)
CA (1) CA3053806A1 (https=)
MX (1) MX2019010732A (https=)
WO (1) WO2018165460A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG11202105746TA (en) 2018-12-20 2021-07-29 Corcept Therapeutics Inc Methods for imaging and treatment of somatostatin-receptor positive tumors
JP2021079146A (ja) * 2021-02-22 2021-05-27 株式会社三洋物産 遊技機
JP7315071B2 (ja) * 2021-03-03 2023-07-26 株式会社三洋物産 遊技機

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9606736D0 (en) 1996-02-19 1996-06-05 Shire International Licensing Therapeutic method
CA2246791A1 (en) 1998-09-01 2000-03-01 Alison Buchan Treatment of endothelium with somatostatin analogues
CA2325169A1 (en) 1999-12-03 2001-06-03 Ndsu Research Foundation Somatostatins and method
US6139845A (en) 1999-12-07 2000-10-31 Allergan Sales, Inc. Method for treating cancer with a neurotoxin
DE60232956D1 (de) 2001-03-23 2009-08-27 Corcept Therapeutics Inc Verfahren zur behandlung von stressbedingten erkrankungen unter verwendung von glucocorticoid-rezepto-spezifischen antagonisten
US7189856B2 (en) 2001-12-28 2007-03-13 Gideon Shapiro Non-peptide somatostatin receptor ligands
CA2558899C (en) 2004-03-09 2013-02-05 Corcept Therapeutics, Inc. Fused ring azadecalin glucocorticoid receptor modulators
GB0428151D0 (en) * 2004-12-22 2005-01-26 Novartis Ag Organic compounds
US20100178663A1 (en) * 2007-05-15 2010-07-15 Waters Technologies Corporation Apparatus And Methods For The Detection Of Plasma Metanephrines
US20100261693A1 (en) 2007-10-17 2010-10-14 Ulmann Andre Method for treating cushing's syndrome
ES2351569B8 (es) 2009-05-07 2012-06-20 Bcn Peptides S.A. Ligandos peptídicos de receptores de somatostatina.
JP5637568B2 (ja) 2009-05-12 2014-12-10 コーセプト セラピューティクス， インコーポレイテッド 固体形態および調製のためのプロセス
ES2999020T3 (en) * 2010-02-05 2025-02-24 Phosphagenics Ltd Carrier comprising non-neutralised tocopheryl phosphate
MY161170A (en) 2011-03-18 2017-04-14 Corcept Therapeutics Inc Pyrimidine cyclohexyl glucocorticoid receptor modulators
WO2013039916A1 (en) * 2011-09-12 2013-03-21 The United States Of America, Represented By The Secretary, Dept. Of Health And Human Services Compositions for and methods of treatment and enhanced detection of non-pituitary tumors
US8859774B2 (en) 2012-05-25 2014-10-14 Corcept Therapeutics, Inc. Heteroaryl-ketone fused azadecalin glucocorticoid receptor modulators
PL3848027T3 (pl) 2013-11-25 2023-07-24 Corcept Therapeutics Incorporated Skondensowane oktahydrozwiązki azadekaliny jako modulatory receptora glukokortykoidowego
AU2016226451B2 (en) * 2015-03-02 2019-12-19 Corcept Therapeutics, Inc. Use of glucocorticoid receptor antagonist and somatostatin analogues to treat ACTH-secreting tumors
US9943526B2 (en) * 2015-04-21 2018-04-17 Corcept Therapeutics, Inc. Optimizing mifepristone levels for cushing's patients

Similar Documents

Publication Publication Date Title
JP2014240408A5 (https=)
JP2018184417A5 (https=)
RU2013102398A (ru) Лечение рака крови
TW200500355A (en) Methods and compositions using immunomodulatory compounds for treatment and management of cancers and other diseases
MXPA05012155A (es) Metodos y composiciones que utilizan compuestos inmunomoduladores para el tratamiento y manejo de canceres y otras enfermedades.
CA2939464A1 (en) Use of anti-ccr5 antibodies in graft versus host disease
WO2003097052A3 (en) Methods and compositions using immunomodulatory compounds for treatment and management of cancers and other diseases
NZ592039A (en) Combination therapy for the treatment of ocular neovascular disorders
MX2019013279A (es) Metodos de tratamiento del sindrome de doose utilizando fenfluramina.
WO2009151569A3 (en) Beta adrenergic receptor agonists for the treatment of b-cell proliferative disorders
EA202191079A1 (ru) Способы лечения синдрома ретта с применением фенфлурамина
JP2012193216A5 (https=)
JP2011516422A5 (https=)
MY199903A (en) Combination therapy with controlled-release cnp agonists
JP2015505564A5 (https=)
JP2020510011A5 (https=)
MY150682A (en) Method for using vasopressin antagonist with anthracycline chemotherapy agents to reduce cardiotoxicity and/or improve survival
IL320452A (en) Combination therapy for prostate cancer
JP2020516646A5 (https=)
JP2022116304A (ja) 血液がんの治療のためのＰＰＡＲγアゴニスト
JP2020512361A5 (https=)
JP2016507493A5 (https=)
MX2020011295A (es) Tratamiento de dermatitis atopica.
JP2017537927A5 (https=)
JP2016515621A5 (https=)